Is Organon & Co. (NYSE:OGN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Organon & Co. at current levels.
A 3.6x forward P/E spinoff drowning in debt that just happens to throw off half a billion in cash, women's health is the call option.
Where OGN is headed
Organon sits at a strange intersection in mid-2026: a company the market treats like a melting ice cube, trading at 3.6x forward earnings, while it generates $529M of free cash flow on a $3.5B market cap. That is a 15% FCF yield. Healthcare companies do not trade at 15% FCF yields unless the market thinks something is about to break. And something might. The $8.5B debt pile inherited from the Merck spin sits on top of an equity base that keeps shrinking, the dividend got cut in 2025 to redirect cash to debt paydown, and the legacy established brands portfolio (Zetia, Singulair, Nasonex) keeps eroding at low single digits a year. That is the bear's bingo card and it is not wrong.
Read the full Compass Direction on OGN
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $13.36).
See the full OGN analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Organon & Co. (NYSE:OGN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Organon & Co. at current levels. A 3.6x forward P/E spinoff drowning in debt that just happens to throw off half a billion in cash, women's health is the call option.
What is OGN's Compass Score?
Organon & Co. scores 90/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for OGN?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the OGN page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.